Galecto Inc

Galecto Inc is an early-stage orphan drug development company.

The company is focusing on novel therapeutics for fibrosis and inflammatory-related diseases, including the lung disease Idiopathic Pulmonary Fibrosis (IPF).

The lead program is in clinical development and addresses a novel therapeutic target for IPF called Galectin-3.

Galecto is listed on Nasdaq New York (ticker: GLTO).

For more information, please contact:

Søren Lemonius, Msc

Managing General Partner

Phone: +45 4081 4889